Rapidly Fatal Infections

Emergency Medicine Clinics of North America

Volumn 26, Issue 2, 2008, Pages 259-279

  Hans, Diana ^a   Kelly, Erin ^a   Wilhelmson, Krista ^a   Katz, Eric D ^a  

^a MARICOPA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AMANTADINE; AMPHOTERICIN B; AMPICILLIN; ANTICONVULSIVE AGENT; ANTISERUM; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; EQUINE MENINGOCOCCAL ANTISERUM; IMMUNOGLOBULIN; LINEZOLID; NAFCILLIN; OSELTAMIVIR; PENICILLIN G; RIBAVIRIN; RIFAMPICIN; RIMANTADINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARBOVIRUS; AVIAN INFLUENZA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CAUSE OF DEATH; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EARLY INTERVENTION; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; EMERGENCY PHYSICIAN; EPIDEMIC MENINGITIS; FATALITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMAGE ANALYSIS; LISTERIA MONOCYTOGENES; MENINGOENCEPHALITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAEGLERIA FOWLERI; NECROTIZING PNEUMONIA; NEISSERIA MENINGITIDIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; SYMPTOM; TOXIC SHOCK SYNDROME; TRAVEL; VACCINATION; VIRUS ENCEPHALITIS;

EID: 41749111796     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2008.01.003     Document Type: Review

References (104)

1. Glikman D., Matushek S., Kahana M., et al. Pneumonia and empyema caused by penicillin-resistant Neisseria meningitidis: a case report and literature review. Pediatrics 117 5 (2006) e1061-e1066
2. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 17 (1913) 553-576
3. Swartz M. Bacterial meningitis: a view of the past 90 years. N Engl J Med 351 (2004) 1826-1828
4. Durand M., Calderwood S., Weber D., et al. Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med 328 (1993) 21-28
5. Schuchat A., Robinson K., Wenger J., et al. Bacterial meningitis in the United States in 1995. N Engl J Med 337 (1997) 970-976
6. Rosenstein N., Perkins B., and Stephens D. Meningococcal disease. N Engl J Med 344 (2001) 1378-1388
7. Dee R.R., and Lorber B. Brain abscess due to Listeria monocytogenes: case report and literature review. Rev Infect Dis 8 (1986) 968
8. Pizon A., Bonner M., Wang H., et al. Ten years of clinical experience with adult meningitis at an urban academic medical center. J Emerg Med 31 4 (2006) 367-370
9. Lavoie F., and Saucier J. Central nervous system infections. In: Marx J., Hockberger R., Walls R., et al. (Eds). Rosen's emergency medicine: concepts and clinical practice. 6th edition, vol. 2 (2006), Mosby Elsevier, Philadelphia 1710-1723
10. Drumheller B., D'Amore J., and Nelson M. A simple clinical decision rule to predict bacterial meningitis in patients presenting to the emergency department. Annals Emergency Medicine 50 3 (2007) S10
11. Quagliarello V., and Scheld W. Treatment of bacterial meningitis. N Engl J Med 336 (1997) 708-716
12. Menaker J., Martin I.B., Hirshorn J.M., et al. Marked elevation of CSF white blood cell count: an unusual case of S pneumoniae meningitis, differential diagnosis, and a brief review of current epidemiology and treatment recommendations. J Emerg Med 29 1 (2005) 37-41
13. Cabral D., Flodmark O., Farrell K., et al. Prospective study of computed tomography in acute bacterial meningitis. J Pediatr 111 (1987) 201-205
14. Centers for Disease Control and Prevention. Division of bacterial and mycotic diseases. Available at: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/meningococcal-g.html. Accessed October15, 2007.
15. van de Beek D., de Gans J., McIntyre P., et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 1 (2007) 10.1002/14651858 CD004405
16. Anderson J. Viral encephalitis and its pathology. Curr Top Pathol 76 (1988) 23-60
17. Centers for Disease Control and Prevention. Division of vector borne infectious diseases: St. Louis encephalitis. Available at: http://www.cdc.gov/ncidod/dvbid/sle/index.html. Accessed October15, 2007.
18. Centers for Disease Control and Prevention. Division of vector borne infectious diseases: Eastern equine encephalitis. Available at: http://www.cdc.gov/ncidod/dvbid/eee/index.html. Accessed October 15, 2007.
19. Deresiewicz R., Thaler S., Hsu L., et al. Clinical and neuroradiographic manifestations of Eastern equine encephalitis. N Engl J Med 336 (1997) 1867-1874
20. Solomon T. Flavivirus encephalitis. N Engl J Med 351 (2004) 370-378
21. Sothern P.M., Smith J.W., Luby J.P., et al. Clinical and laboratory features of epidemic St. Louis encephalitis. Ann Intern Med 71 (1969) 681-689
22. Wasay M., Diaz-Arrastia R., Suss R., et al. St. Louis encephalitis: a review of 11 cases in a 1995 Dallas, Texas epidemic. Arch Neurol 57 (2000) 114-118
23. Demaerel P., Wilms G., Robberecht W., et al. MRI of herpes simplex encephalitis. Neuroradiology 34 (1992) 490-493
24. Farber S., Hill A., Connerly M.L., et al. Encephalitis in infants and children caused by the virus of the eastern variety of equine encephalitis. JAMA 114 (1940) 1725-1731
25. Rahal J.J., Anderson J., Rosenberg C., et al. Effect of interferon alpha 2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 190 (2004) 1084-1087
26. Golomb M.R., Durand M.L., Schaefer P.W., et al. A case of immunotherapy-responsive eastern equine encephalitis with diffusion-weighted imaging. Neurology 56 (2001) 420-421
27. Bennett N. Naegleria. Available at: http://www/emdicine.com/ped/topic2807.htm. Accessed October 18, 2007.
28. Centers for Disease Control and Prevention. Division of parasitic diseases. Available at: http://www.cdc.gov/ncidod/dpd/parasites/naegleria.htm. Accessed October 18, 2007.
29. Kahn C. Arizona teen becomes sixth victim this year of brain eating amoeba. Available at: http://www.foxnews.com/story/0,2933,298338,00.html. Accessed October 26, 2007.
30. Pernin P., Pélandakis M., Rouby Y., et al. Comparative recoveries of Naegleria fowleri amoebae from seeded river water by filtration and centrifugation. Appl Environ Microbiol 64 3 (1998) 955-959
31. US Food and Drug Administration, Department of Health and Human Services. Acanthamoeba spp., Naegleria fowleri and other Amoebae. Available at: http://www/cfsan.fda.gov/∼mow/chap29.html. Accessed September 22, 2007.
32. Marciano-Cabral F., and Cabral G.A. The immune response to Naegleria fowleri amebae and pathogenesis of infection. FEMS Immunol Med Microbiol 51 2 (2007) 243-259
33. Centers for Disease Control and Prevention. Primary amebic meningoencephalitis, Georgia, 2002. MMWR Morb Mortal Wkly Rep 52 40 (2003) 962-964
34. Seidel J.S., Harmatz P., Visvesvara G.S., et al. Successful treatment of primary amebic meningoencephalitis. N Engl J Med 306 (1982) 346-348
35. Stevens D.L. Invasive group A streptococcus infections. Clin Infect Dis 14 (1992) 2-13
36. Laupland K.B., Davies H.D., Low D.E., et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection: Ontario Group A Streptococcal Study Group. Pediatrics 105 (2000) E60
37. Hajjeh R.A., Reingold A., Weil A., et al. Toxic shock syndrome in the United States: surveillance update, 1979-1996. Emerg Infect Dis 5 (1999) 807
38. Reduced incidence of menstrual toxic-shock syndrome: United States 1980-1990. MMWR Morb Mortal Wkly Rep 39 (1990) 421
39. O'Brien K.L., Beall B., Barrett N.L., et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. Clin Infect Dis 35 (2002) 268
40. Reingold A.L., Broome C.V., Gaventa S., et al. Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis 11 Suppl 1 (1989) S28
41. Bartlett P., Reingold A.L., Graham D.R., et al. Toxic shock syndrome associated with surgical wound infections. JAMA 247 (1982) 1448
42. Schlievert P.M. Role of superantigens in human disease. J Infect Dis 167 (1993) 997
43. Schlievert P.M. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet 1 (1986) 1149
44. Bohach G.A., Fast D.J., Nelson R.D., et al. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 17 (1990) 251
45. Hauser A.R., Stvens D.L., Kaplan E.L., et al. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 29 (1991) 1562
46. Norrby-Teglund A., Newton D., Kotb M., et al. Superantigenic properties of the group A streptococcal exotoxin SpeF. Infect Immun 62 (1994) 5227
47. Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 46 RR-10 (1997) 1
48. Vuzevski V.D., van Joost T., Wagenvoort J.H., et al. Cutaneous pathology in toxic shock syndrome. Int J Dermatol 28 (1989) 94
49. Chesney P.J., Davis J.P., Purdy W.K., et al. Clinical manifestations of toxic shock syndrome. JAMA 246 (1981) 741
50. Kain K.C., Schulzer M., and Chow A.W. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 16 (1993) 100
51. Bisno A.L., and Stevens D.L. Streptococcal infections in skin and soft tissues. N Engl J Med 334 (1996) 240
52. Davis J.P., Chesney P.J., Want P.J., et al. Toxic shock syndrome. N Engl J Med 303 (1980) 1429
53. Reingold A.L., Hargrett N.T., Shands K.N., et al. Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med 96 (1982) 875
54. Davis J.P., Osterholm M.T., Helms C.M., et al. Tri-state toxic-shock syndrome study. II. Clinical and laboratory findings. J Infect Dis 145 (1982) 441
55. Schlievert P.M., and Kelly J.A. Clindamycin-induced suppression of toxic-shock syndrome: associated exotoxin production. J Infect Dis 149 (1984) 471
56. Stevens D.L., Wallace R.J., Hamilton S.M., et al. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 42 (2006) 729
57. Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 13 (1952) 389
58. Stevens D.L., Bryant A.E., and Yan S. Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents 4 (1994) 297
59. Mascini E.M., Jansze M., Schouls L.M., et al. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 18 (2001) 395
60. Gemmell C.G., Peterson P.K., Schmeling D., et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 67 (1981) 1249
61. Zimbelman J., Palmer A., and Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 18 (1999) 1096
62. Barry W., Hudgins L., Donta S., et al. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 267 (1992) 3315
63. Darenberg J., Ihendyane N., Sjolin J., et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37 (2003) 333
64. Darenberg J., Soderquist B., Normark B.H., et al. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 38 (2004) 836
65. Todd J.K., Ressman M., Caston S.A., et al. Corticosteroid therapy for patients with toxic shock syndrome. JAMA 252 (1984) 3399
66. Benner E.J., and Kayser F.H. Growing clinical significance of methicillin-resistant Staphylococcus aureus. Lancet 2 (1968) 741
67. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 355 (2006) 666
68. Hidron A.I., Kourbatova E.V., Halvosa J.S., et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 41 (2005) 159
69. Salgado C.D., Farr B.M., and Calfee D.P. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 36 (2003) 131
70. Lina G., Piedmont Y., Godail-Gamot F., et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29 5 (1999) 1128-1132
71. Naimi T.S., LeDell K.H., Como-Sabetti K., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290 (2003) 2976
72. Boyle-Vavra S., and Daum R.S. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 87 (2007) 3
73. Labandeira-Rey M., Couzon F., Boisset S., et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315 (2007) 1130
74. Francis J.S., Doherty M.C., Lopatin U., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40 (2005) 100
75. Hageman J.C. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 12 (2006) 894
76. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza: Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 56 (2007) 325
77. Dufour P., Gillet Y., Bes M., et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 35 (2002) 819
78. Sanford B.A., and Ramsay M.A. Bacterial adherence to the upper respiratory tract of ferrets infected with influenza A virus. Proc Soc Exp Biol Med 185 (1987) 120-128
79. Tashiro M., Ciborowski P., Reinacher M., et al. Synergistic role of staphylococcal proteases in the induction of influenza virus pathogenicity. Virology 157 (1987) 421-430
80. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
81. Micek S.T., Dunne M., and Kollef M.H. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 128 4 (2005) 2732-2738
82. Gillet Y., Vanhems P., Lina G., et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 45 3 (2007) 315-321
83. Gillet Y., Issartel B., Vanhems P., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent persons. Lancet 359 (2002) 753
84. Moise P.A., and Schentag J.J. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infection. Int J Antimicrob Agents 16 (2000) S31-S34
85. Stevens D.L., Herr D., Lampiris H., et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34 (2002) 1481-1490
86. Kollef M.H., Rello J., Cammarata S.K., et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30 (2004) 388-394
87. Rubinstein E., Cammarata S.K., Oliphant T.H., et al. Linezolid versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32 (2001) 402-412
88. Powers J.H., Ross D.B., Lin D., et al. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 126 (2004) 314-316
89. Reimel B.A., Krishnadasen B., Cuschieri J., et al. Surgical management of acute necrotizing lung infections. Can Respir J 13 7 (2006) 369-373
90. WHO Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (2003), World Health Organization, Geneva (Switzerland). http://www.who.int/csr/sars/country/table2004_04_21/en/print.html Accessed October 26, 2007
91. In the absence of SARS-CoV transmission worldwide: guidance for surveillance, clinical, and laboratory evaluation, and reporting version 2 (2005), Centers for Disease Control, Atlanta (GA). http://www.cdc.gov/ncidod/sars/absenceofsars.htm Accessed October 26, 2007
92. Wong R.S., and David S.H. Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis 10 (2004) 339-341
93. Hsu L.Y., Lee C.C., Green J.A., et al. Severe Acute Respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 9 (2003) 713-717
94. Lee N., Hui D., Wu A., et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348 (2003) 1986-1994
95. Booth C.M., Matukas L.M., Tomlinson G.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289 (2003) 2801-2809
96. Chan P.K., To W.K., Ng K.C., et al. Laboratory diagnosis of SARS. Emerg Infect Dis 10 (2004) 825-831
97. WHO hospital infection control guidance for severe acute respiratory syndrome (2003), World Health Organization, Geneva (Switzerland). http://www.who.int/csr/sars/infectioncontrol/en/ Accessed October 26, 2007
98. Avian influenza: current situation (2007), Centers for Disease Control, Atlanta (GA). http://www.cdc.gov/flu/avian/outbreaks/current.htm Accessed October 26, 2007
99. WHO cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO (2007), World Health Organization, Geneva (Switzerland). http://www.who.int/xsr/disease/avian_influenza/country/cases_table_2007_10_25/en/print/ Accessed October 26, 2007
100. Hien T.T., Liem N.T., Dung N.T., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350 (2004) 1179-1188
101. Oner A.F., Bay A., Arslan S., et al. Avian influenza A (H5N1) in Eastern Turkey in 2006. N Engl J Med 355 (2006) 2179-2185
102. WHO clinical management of human infection with avian influenza A (H5N1) virus (2007), World Health Organization, Geneva (Switzerland). http://www.who.int/csr/disease/avian_influenza/guidelines/clinicalmanage07/en/index.html Accessed October 26, 2007
103. Centers for Disease Control. Embargo of birds from specified countries (2007), Centers for Disease Control, Atlanta (GA). http://www.cdc.gov/flu/avian/outbreaks/embargo.htm Accessed October 26, 2007
104. Interim recommendations for infection control in health care facilities caring for patients with known or suspected avian influenza (2004), Centers for Disease Control, Atlanta (GA). http://www.cdc.gov/flu/avian/professional/infect-control.htm Accessed October 26, 2007